{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:40:19Z","timestamp":1792172419780,"version":"4.4.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:p>To investigate the regularity and characteristics of adverse drug reaction (ADR) of reactive cutaneous capillary endothelial proliferation caused by Camrelizumab, so as to provide reference for clinical rational use of drugs. Searching for case reports of Camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP) in databases such as China Biology Medicine disc, VIP Database, CNKI, Wanfang Medical, PubMed, Wiley online library, Embase with \u201cCarritzumab\/Ericab,\u201d \u201cSHR-1210,\u201d \u201cReactive cutaneous capillary endothelial proliferation,\u201d \u201cReactive capillary hemangiomas,\u201d and \u201cCapillary proliferation\u201d as search terms. The retrieval time is from the establishment of the database to February 2022. After eliminating clinical trials and incomplete literature, information of patients included in the literature was analyzed, which included gender, age, reason for medication, usage and dosage, time of ADR, concomitant medication, clinical manifestations, intervention measures, outcomes of patients, etc. A total of 11 articles involving 16 patients were included, including 11 males and five females, with an average age of 60.5 years. Reasons for medication included nine cases of non-small cell lung cancer (NSCLC), four cases of liver cancer, one case of small cell lung cancer (SCLC), one case of synovial sarcoma, and one case of Hodgkin lymphoma. Thirteen patients recorded in detail that the dosage of Camrelizumab was 200 mg, and the frequency of medication was q2w~q4w. Eight patients were treated with Camrelizumab alone, and eight patients were treated with combined medication. RCCEP occurred in nine patients after the first medication, and in seven patients after two-four cycles of medication, the average medication cycle was two cycles, and the average occurrence time was 12.5 days after the last medication. The main clinical manifestations were that several different sizes of growths such as red nevus-like, pearl-like, and mulberry-like growths appear on the head, face, neck, torso, limbs, and other parts of the body, all of which were grade 1-2. The RCCEP of all patients was controlled after treatment. During the treatment, 11 patients were stable and five patients were local remission. RCCEP is caused by Camrelizumabis a special skin immune response, which will not cause life-threatening to patients. However, clinicians and pharmacists should be familiar with the characteristics and regularities of the adverse reaction, to do a good job in medication monitoring and management, as for ensuring the safety of patients with medication.<\/jats:p>","DOI":"10.4103\/ijd.ijd_343_22","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T16:39:18Z","timestamp":1724949558000},"page":"318-326","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab: Sixteen Case Reports"],"prefix":"10.4103","volume":"68","author":[{"given":"Pang","family":"Hui-Mei","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Guangxi International Zhuang Medical Hospital, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"Guang-Ming","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xiao-Ling","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangxi International Zhuang Medical Hospital, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Hong-Liang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Si-Jun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangxi International Zhuang Medical Hospital, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250921","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5152\/eurasianjmed.2018.18194","article-title":"Immunological agents used in cancer treatment","volume":"51","author":"Simsek","year":"2019","journal-title":"Eurasian J Med"},{"key":"R2-20250921","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: First global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"R3-20250921","doi-asserted-by":"crossref","first-page":"173","DOI":"10.20892\/j.issn.2095-3941.2018.0172","article-title":"Reactive capillary hemangiomas: A novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210","volume":"16","author":"Chen","year":"2019","journal-title":"Cancer Biol Med"},{"key":"R4-20250921","first-page":"65","article-title":"A case of reactive cutaneous capillary endothelial proliferation caused by camrelizumab","volume":"18","author":"Yu","year":"2021","journal-title":"Chin J Drug Appl Monitor"},{"key":"R5-20250921","first-page":"574","article-title":"A case of camrelizumab-induced reactive cutaneous capillary endothelial proliferation","volume":"40","author":"Jiang","year":"2021","journal-title":"Gansu Med J"},{"key":"R6-20250921","first-page":"725","article-title":"Capillaries hyperplasia induced by Carilizumab: A case report","volume":"24","author":"Wei","year":"2021","journal-title":"China Pharmacist"},{"key":"R7-20250921","first-page":"160","article-title":"Reactive cutaneous capillary endothelial proliferation caused by camrelizumab","volume":"23","author":"Wang","year":"2021","journal-title":"ADRJ"},{"key":"R8-20250921","first-page":"219","article-title":"Reactive capillary hemangiomas caused by PD-1 inhibitor (Calerizumab): A report of three cases and literature review","volume":"36","author":"Long","year":"2020","journal-title":"Chin J Lepr Skin Dis"},{"key":"R9-20250921","first-page":"252","article-title":"Reactive cutaneous capillary endothelial proliferation caused by the PD-1 inhibitor camrelizumab during the treatment of malignant tumors: Two case reports","volume":"54","author":"Wei","year":"2021","journal-title":"Chin J Dermatol"},{"key":"R10-20250921","doi-asserted-by":"crossref","first-page":"12471","DOI":"10.2147\/OTT.S279004","article-title":"A Partial response of pulmonary pleomorphic carcinoma to camrelizumab (PD1 monoclonal antibody) monotherapy: A case report","volume":"13","author":"Chen","year":"2020","journal-title":"Onco Targets Ther"},{"key":"R11-20250921","doi-asserted-by":"crossref","first-page":"624","DOI":"10.12998\/wjcc.v8.i3.624","article-title":"Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report","volume":"8","author":"Yu","year":"2020","journal-title":"World J Clin Cases"},{"key":"R12-20250921","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1111\/ijd.15606","article-title":"Reactive capillary hemangiomas induced by camrelizumab in a patient with hepatocarcinoma","volume":"60","author":"Zhang","year":"2021","journal-title":"Int J Dermatol"},{"key":"R13-20250921","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/0284186X.2019.1567935","article-title":"Reactive capillary hemangiomas induced by camrelizumab (SHR-1210), an anti-PD-1 agent","volume":"58","author":"Teng","year":"2019","journal-title":"Acta Oncol"},{"key":"R14-20250921","first-page":"232","article-title":"Reactive cutaneous capillary endothelial proliferation caused by PD-1 inhibitor camrelizumab: Two cases report","volume":"38","author":"Zhang","year":"2022","journal-title":"Chin J Lepr Skin Dis"},{"key":"R16-20250921","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00018-017-2686-7","article-title":"CD4 and CD8 T lymphocyte interplay in controlling tumor growth","volume":"75","author":"Ostroumov","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"R17-20250921","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"R18-20250921","first-page":"1066","article-title":"Clinicopathological report of cutaneous capillary endothelial proliferation related with anti-PD-1 monoclonal antibody SHR-1210 in the treatment of primary hepatic carcinoma","volume":"22","author":"Wang","year":"2017","journal-title":"Chin Clin Oncol"},{"key":"R19-20250921","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/19420862.2018.1550321","article-title":"Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement","volume":"11","author":"Finlay","year":"2019","journal-title":"MAbs"},{"key":"R20-20250921","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma","volume":"5","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R21-20250921","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"key":"R22-20250921","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: Results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"R23-20250921","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/j.jtho.2019.08.425","article-title":"A randomized phase 3 study of camrelizumab plus chemotherapy as 1st line therapy for advanced\/metastatic non-squamous non-small cell lung cancer","volume":"14S","author":"Zhou","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R24-20250921","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 Antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"R25-20250921","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1200\/JCO.2019.37.15_suppl.9112","article-title":"Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced nonsquamous NSCLC with wild-type EGFR and ALK","volume":"37S","author":"Zhou","year":"2019","journal-title":"J Clin Oncol"},{"key":"R26-20250921","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41416-018-0100-3","article-title":"Safety, anti-tumour activity, and pharmacokinetics of fixed- dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: A dose-escalation, phase 1 study","volume":"119","author":"Mo","year":"2018","journal-title":"Br J Cancer"},{"key":"R27-20250921","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s40425-019-0636-7","article-title":"Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: Findings from recent advances in landmark trials","volume":"7","author":"Lv","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R28-20250921","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-020-00886-2","article-title":"Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: Data derived from a multicenter phase 2 trial","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R29-20250921","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"key":"R30-20250921","article-title":"A retrospective study of reactive cutaneous capillary endothelial proliferation induced by Camrelizumab","author":"Qu","year":"2020","journal-title":"2020 CSCO Proceedings of annual Conference: Innovative Drug Session"},{"key":"R31-20250921","first-page":"840","article-title":"Expert consensus on clinical diagnosis and treatment of reactive cutaneous capillary hyperplasia induced by Camrelizumab","volume":"25","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"R33-20250921","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): A multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_343_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:43:11Z","timestamp":1787067791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_343_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_343_22","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}